Brepocitinib Achieves First Positive Phase 3 Trial Result in Dermatomyositis: The VALOR Study
View StudyPlain-Language Summary
A landmark phase 3 trial has found that brepocitinib, an oral TYK2/JAK1 inhibitor, significantly improved a comprehensive measure of disease activity in adults with dermatomyositis that had not responded adequately to prior therapies. The VALOR trial enrolled 241 patients across 90 sites globally, making it the largest and longest interventional study ever conducted in dermatomyositis and the first 52-week placebo-controlled trial to achieve a positive result for a targeted therapy in this disease. With FDA Priority Review designation in hand, brepocitinib may become the first drug specifically approved for dermatomyositis as early as 2026.
Abstract
Dermatomyositis is an idiopathic inflammatory myopathy characterized by proximal muscle weakness, distinctive skin manifestations including heliotrope rash and Gottron's papules, and systemic complications that can affect the lungs, heart, and joints. Its pathogenesis involves prominent interferon signaling, particularly through the type I interferon axis, driven by dysregulated immune activation through TYK2 and JAK1 kinases. No therapies are specifically approved for dermatomyositis, and management has depended on glucocorticoids and off-label immunosuppressants with variable efficacy and significant long-term toxicity.
Brepocitinib is a selective, oral TYK2 and JAK1 inhibitor designed to reduce the interferon-driven inflammation central to dermatomyositis pathology. VALOR was a phase 3, randomized, double-blind, placebo-controlled trial enrolling 241 adults with active dermatomyositis resistant to prior therapy across 90 investigational sites worldwide. Participants were randomized to brepocitinib 30 mg, brepocitinib 15 mg, or placebo once daily for 52 weeks. The primary endpoint was the Total Improvement Score (TIS), a validated composite measure assessing muscle strength, physical function, extramuscular disease activity, and patient-reported outcomes.
At week 52, brepocitinib 30 mg achieved a mean TIS of 46.5 compared to 31.2 in the placebo group, a statistically and clinically significant 15.3-point difference (p=0.0006). The 30 mg dose also demonstrated significant benefits in skin disease severity, glucocorticoid tapering capacity, and functional disability; the 15 mg dose did not meet the primary endpoint. These results represent the first positive outcome in a registrational phase 3 trial for a targeted therapy in dermatomyositis. The FDA has granted Priority Review to brepocitinib's NDA for dermatomyositis, with a PDUFA date expected in the third quarter of 2026.